MARC보기
LDR00000nmm u2200205 4500
001000000330723
00520241104144955
008181129s2018 ||| | | | eng d
020 ▼a 9780438110380
035 ▼a (MiAaPQ)AAI10902377
040 ▼a MiAaPQ ▼c MiAaPQ ▼d 248032
0491 ▼f DP
0820 ▼a 615
1001 ▼a El-Refai, Sherif M.
24510 ▼a Exploring the Effect of Chronic Inflammation on Response to Immune Checkpoint Inhibitors in Cancer.
260 ▼a [S.l.] : ▼b University of Kentucky., ▼c 2018
260 1 ▼a Ann Arbor : ▼b ProQuest Dissertations & Theses, ▼c 2018
300 ▼a 146 p.
500 ▼a Source: Dissertation Abstracts International, Volume: 79-11(E), Section: B.
5021 ▼a Thesis (Ph.D.)--University of Kentucky, 2018.
520 ▼a Precision medicine has allowed for the development of monoclonal antibodies that unmask the anti-tumor immune response. These agents have provided some patients durable clinical benefit. However, PD-1 and PD-L1 inhibitor therapies are effective
590 ▼a School code: 0102.
650 4 ▼a Pharmaceutical sciences.
690 ▼a 0572
71020 ▼a University of Kentucky. ▼b Pharmaceutical Sciences.
7730 ▼t Dissertation Abstracts International ▼g 79-11B(E).
773 ▼t Dissertation Abstract International
790 ▼a 0102
791 ▼a Ph.D.
792 ▼a 2018
793 ▼a English
85640 ▼u http://www.riss.kr/pdu/ddodLink.do?id=T15000364 ▼n KERIS
980 ▼a 201812 ▼f 2019
990 ▼a 관리자 ▼b 관리자